Online inquiry

IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14535MR)

This product GTTS-WQ14535MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL13&IL4 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001354991.2; NM_000589.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596; 3565
UniProt ID P35225; P05112
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14535MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13892MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-2176
GTTS-WQ235MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ3181MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ14356MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG7716
GTTS-WQ15099MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ST2146
GTTS-WQ4409MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-663513
GTTS-WQ14107MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA aNGF75
GTTS-WQ10428MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-2495655
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW